What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?
News
The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.
Are you attending Real Psychiatry this weekend?
The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.
Celebrating the life of a psychiatrist fascinated with death.
Transforming sports psychiatry, Derek H. Suite, MD, discusses how he delivers mental health care for elite athletes. From courtside to locker rooms, he builds trust, optimizes performance, and pioneers strategies to meet the unique demands of the sports ecosystem.
Understanding the complex relationship between substance use and mental health is critical to providing thorough and well-informed evaluations. Let's take a look at the relationship between cannabis and criminal responsibility.
Johnson & Johnson today announced that they will acquire all outstanding shares of Intra-Cellular Therapies, as well as their therapeutic pipeline, including lumateperone.
How can you manage health care coordination for patients who traverse various levels of care?
The LA fires demonstrate the incredibly difficult process of loss and grieving past selves…
Learn more about the latest research on different approaches to treatments for major depressive disorder (MDD).
From navigating crises to championing inclusive, patient-centered care, psychiatric leaders are redefining mental health policies, dismantling stigma, and driving transformative change across communities.
Check out these examples of neuroplasticity.
What actions can mental health clinicians take to reduce climate instability?
Jessi Gold, MD, MS, writes about the emotional challenges of healthcare during the COVID-19 pandemic. Through patient stories and her own reflections, she uncovers what happens when clinicians are asked to "feel."
How can we optimize and expand our knowledge of neuroplasticity?
The winner of the Chrismukkah essay contest is…
Join us in congratulating Dr Tasman on his recent win of the Hartford HealthCare Institute of Living’s 2024 C. Charles Burlingame, MD, award.
Welcome to the year-long celebration.
The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.
Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.
There is no accurate profile of who will become a school shooter, so mental health clinicians should react as they would with any patient threatening violence: inquire, gain collateral data, assess, and respond.
Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?
Nuclear war capability: why we should be worried psychiatrically.
Do you want to be featured in a future Special Report? Check out our January theme!
How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?
Psychiatric Times: Supporting clinicians, promoting conversations, and improving patient care over the past 40 years.
How much fear is too much?
How will the definition of assisted death (AD) as medical care impact its utilization?
Essay contest winners will be announced on January 6th.
Advertisement
Advertisement